Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions

P. Zhao; M. Rowland; S. M. Huang

doi:10.1038/clpt.2012.68

Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions

P. Zhao, M. Rowland, S. M. Huang

Research output: Contribution to journal › Article › peer-review

Abstract

Physiologically based pharmacokinetic (PBPK) models are increasingly used by drug developers to evaluate the effect of patient factors on drug exposure. Between June 2008 and December 2011, the Office of Clinical Pharmacology at the US Food and Drug Administration (FDA) received 25 submissions containing PBPK analyses. This report summarizes the essential content of a PBPK analysis needed in a regulatory submission for the purpose of addressing clinical pharmacology questions.

Original language	English
Pages (from-to)	17-20
Number of pages	3
Journal	Clinical Pharmacology and Therapeutics
Volume	92
Issue number	1
DOIs	https://doi.org/10.1038/clpt.2012.68
Publication status	Published - Jul 2012

Access to Document

10.1038/clpt.2012.68

Cite this

@article{f60a1dd04ba742b2898c1f146f12cfcd,

title = "Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions",

abstract = "Physiologically based pharmacokinetic (PBPK) models are increasingly used by drug developers to evaluate the effect of patient factors on drug exposure. Between June 2008 and December 2011, the Office of Clinical Pharmacology at the US Food and Drug Administration (FDA) received 25 submissions containing PBPK analyses. This report summarizes the essential content of a PBPK analysis needed in a regulatory submission for the purpose of addressing clinical pharmacology questions.",

author = "P. Zhao and M. Rowland and Huang, {S. M.}",

year = "2012",

month = jul,

doi = "10.1038/clpt.2012.68",

language = "English",

volume = "92",

pages = "17--20",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "John Wiley & Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions

AU - Zhao, P.

AU - Rowland, M.

AU - Huang, S. M.

PY - 2012/7

Y1 - 2012/7

N2 - Physiologically based pharmacokinetic (PBPK) models are increasingly used by drug developers to evaluate the effect of patient factors on drug exposure. Between June 2008 and December 2011, the Office of Clinical Pharmacology at the US Food and Drug Administration (FDA) received 25 submissions containing PBPK analyses. This report summarizes the essential content of a PBPK analysis needed in a regulatory submission for the purpose of addressing clinical pharmacology questions.

AB - Physiologically based pharmacokinetic (PBPK) models are increasingly used by drug developers to evaluate the effect of patient factors on drug exposure. Between June 2008 and December 2011, the Office of Clinical Pharmacology at the US Food and Drug Administration (FDA) received 25 submissions containing PBPK analyses. This report summarizes the essential content of a PBPK analysis needed in a regulatory submission for the purpose of addressing clinical pharmacology questions.

U2 - 10.1038/clpt.2012.68

DO - 10.1038/clpt.2012.68

M3 - Article

SN - 0009-9236

VL - 92

SP - 17

EP - 20

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 1

ER -

Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions

Abstract

Access to Document

Fingerprint

Cite this